logo2020B taglinecrop

124 Byte Drive, Frederick, MD 21702
Contact Us Form

"Reforming Healthcare by preventing diseases through next generation vaccines”.

About Biological Mimetics, Inc.: New Generation Antigens, Vaccines, & Antibodies

Biological Mimetics, Inc. (“BMI”) was formed in 1996 to commercialize innovative pharmaceutical products that will improve the quality of life and overall state of public health by combating resistant and emerging diseases in human and veterinary medicine.

Our mission philosophy is to remain a creative and innovative biotechnology firm dedicated to improving the quality of life and overall state of public health. Conducted through the application of novel technologies for the development and commercialization of human and veterinary biologics to address a long list of hitherto intractable disease targets involving viruses, bacteria, parasites, and cancer.

Based on the Company’s elucidation of a common vaccine evading mechanism of antigenic variation known as “Deceptive Imprinting” used by microbial pathogens and cancer cells, the company has developed a proprietary core technology termed “Immune Dampening and Refocusing”, which uses immune dampening and refocusing to circumvent such evasion mechanisms to: (1) generate vaccines against pathogens for which no effective vaccine exists and (2) improve on the strain or serotype restricted protection of previously tried and currently licensed and used human and veterinary vaccines. In addition, the technology is able to alter the natural antigenicity and immunogenicity of targeted protein antigens to induce and select for unique monoclonal antibodies that can be used for therapeutic, diagnostic, and research purposes. Therapeutic proteins and biologics can also be immune dampened to improve on their biological half-life and safety profiles.

BMI was founded in 1996 by scientists from the National Cancer Institute and initiated operations in 1997. The company’s headquarters and research and development facilities are located in Frederick, Maryland.

Since obtaining proof-of-principle for its Immune Dampening and Refocusing technology in multiple systems, BMI is actively seeking strategic partners to accelerate the development of products using this technology.

Gregory J. Tobin, PhD


President and CEO. Dr. Tobin has led research and technical programs at BMI since 1999.  A vaccinologist and molecular biologist, Dr. Tobin has significant experience in project direction and management; design, planning, and execution of research projects; and coordination of multi-site studies.  Dr. Tobin fosters a highly interactive research and development group to apply the Company’s two proprietary technologies (Novel Inactivated Vaccines and Immune Refocusing Technology) to the design of improved vaccines. 

Current research projects employ the technology used in UltraIPV to the derivation of vaccines against two antibiotic-resistant bacteria, Acinetobacter baumannii and MRSA. In addition, Dr. Tobin’s work includes the use of Immune Refocusing in the design of the first vaccine against human rhinovirus (HRV) and of a broadly protective influenza vaccine.  Dr. Tobin has been the Principal Investigator or technical lead on twelve NIH grants, seven DOD research contracts, and several grants funded by other agencies or companies.

David S. Silberstein, PhD

Dave cropframeDirector and Scientific Advisor. Dr. Silberstein received his PhD in Microbiology at Columbia University and Postdoctoral training at Harvard Med School/Brigham & Women’s Hospital.  He continued for seven years with a faculty appointment at Harvard, leading an NIH-funded research team studying the biochemistry of lung inflammation. 

This was followed by 20 years at AstraZeneca Pharmaceuticals where he had leadership roles in genomics, translational science, company-wide portfolio management, and science support for two products through launch to aggregate sales of greater than $30 billion. Since 2013, he has worked as an advisor and company officer with a number of early stage biotech companies and as a consultant to investment firms.

Drs. Dollery & MacLeoad


Drs. Stephen Dollery and David MacLeod discuss antiviral assays.

John Tobin and Claire

john claire4

John Tobin and Claire are having a discussion about important topics.

A. Gregory Kelly

Greg Kellycrop

Chair, Board of Directors. Greg Kelly, M.S., M.B.A., has been an active member of Maryland’s emerging business community for over 35 years. He has invested in a number of early-stage companies, and he has founded, been a Board Member of, or been a strategic advisor and financial consultant to numerous other companies.

For 20 years, Greg served in the Health Care & Life Sciences practice of KPMG in Baltimore, where he managed or provided public and private offerings assistance, financial structuring advice , transactions services, small and large company performance improvement initiatives, and attestation services.

Greg is currently a founder, the Co-President, the Chief Science Officer and the Chief Financial Officer of Blue Ocean Biosystems, Inc. in Easton, Maryland, and the Managing Director of Acadine Ventures, LLC.

Barry Henderson, M.Sc.

barryDirector of Business Development. Barry holds a M.Sc. in Bacteriology & Virology and M.Sc. Molecular Pathology both from University of Manchester. He has over 20 years business development experience working with academics, businesses and clinicians to develop and progress innovative technologies to market.

He recently completed a three-year contract as Business Development Director, leading the Life Sciences sector with Invest NI’s US Office, and brings a wealth of relevant experience, having previously held roles in biomedical research, sales & marketing within the biotech sector and life science innovation management with Ulster University.

Our Scientists at Work


Scientists Steve Dollery, Taralyn Wiggins, Ruth Bushnell, and David MacLeod wrap up analyzing polio neutralization assays.

Our Company Morale Officers


Here, Claire (left) is getting pointers from our experienced, Chief Morale Officer, Vesper (right).

For further information, please use our Contact Us Form

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.